Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115247) titled 'Adebrelimab and famitinib alone or combined with short-course chemotherapy as the first-line treatment for PD-L1-positive advanced non-small cell lung cancer: a clinical study' on Dec. 24, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Changzhou First People's Hospital
Condition:
Non-small cell lung cancer
Intervention:
ICS+TKI:Adebrelimab + Famitinib (A treatment cycle lasts for 3 weeks)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: ICS+TKI:40;ICS+TKI+CHEMO:40;
Countries of Recruitment:
China
To know more, vis...